抗胆碱能药物影响社区老年人从正常认知向轻度认知障碍的转变
本研究为观察性队列研究,纳入350例65岁以上无痴呆的基层医疗老年人,平均随访3.2年。采用抗胆碱能认知负担量表评估抗胆碱能药物暴露,发现强抗胆碱能药物总标准日剂量增加与正常认知向轻度认知障碍转变的 odds 升高相关(OR 1.15,95%CI 1.01-1.31,p=0.0342),但不影响轻度认知障碍逆转为正常认知(OR 0.95,95%CI 0.86-1.05,p=0.3266)。
要点
- 强抗胆碱能药物累积剂量增加与正常认知向MCI转变风险升高相关。
- 强抗胆碱能药物未显示影响MCI逆转为正常认知。
- 对认知正常老年人可考虑将抗胆碱能药物作为可干预风险因素进行处方优化。
核心结论
- 强抗胆碱能药物总标准日剂量增加与正常认知向轻度认知障碍转变的 odds 升高独立相关。
- 强抗胆碱能药物未显著影响轻度认知障碍逆转为正常认知。
研究设计与样本
- 观察性队列研究,平均随访3.2年,共完成978次诊断评估。
- 纳入350例65岁及以上、无痴呆且接受基层医疗的老年人。
- 认知诊断由专家小组在基线和每年至第4年进行,采用两阶段筛查和共识性神经精神检查。
- 抗胆碱能暴露通过药房调配和索赔记录确定,使用抗胆碱能认知负担量表识别入组前10年及研究期间每年调配的药物。
主要发现
- 与认知稳定相比,强抗胆碱能药物总标准日剂量增加与正常认知向轻度认知障碍转变的 odds 升高相关(OR 1.15,95%CI 1.01-1.31,p=0.0342)。
- 与轻度认知障碍稳定相比,强抗胆碱能药物未影响轻度认知障碍逆转为正常认知(OR 0.95,95%CI 0.86-1.05,p=0.3266)。
临床怎么用
- 在认知正常的老年人中,可考虑评估抗胆碱能药物负荷并将其作为潜在可干预的认知损害风险因素。
- 去处方干预研究可测试减少强抗胆碱能药物能否降低正常认知向轻度认知障碍转变的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To determine the influence of anticholinergic medications on transitions in cognitive diagnosis of older adults in primary care. DESIGN: This observational cohort study was conducted over a mean follow-up of 3.2 years. Anticholinergic exposure was defined by pharmacy dispensing and claims records. Cognitive diagnosis was performed by an expert panel at baseline and annually up to 4 years. DATA SOURCE: Medication exposure and other clinical data were extracted from the Indiana Network for Patient Care (INPC). The cognitive diagnosis was derived from a cognitive screening and diagnosis study. PARTICIPANTS: A total of 350 adults 65 years and older without dementia and receiving primary care in a safety net health care system. MEASUREMENT AND MAIN RESULTS: Cognitive diagnosis followed a two-phase screening and consensus-based neuropsychiatric examination to determine a baseline diagnosis as normal cognition, mild cognitive impairment (MCI), or dementia, with a follow-up neuropsychiatric examination and consensus-based diagnosis repeated annually. The Anticholinergic Cognitive Burden scale was used to identify anticholinergics dispensed up to 10 years before enrollment and annually throughout the study. A total standard daily dose of anticholinergics was calculated by using pharmacy dispensing data from the INPC. Among 350 participants, a total of 978 diagnostic assessments were completed over a mean follow-up of 3.2 years. Compared with stable cognition, increasing use of strong anticholinergics calculated by total standard daily dose increased the odds of transition from normal cognition to MCI (odds ratio [OR] 1.15, 95% confidence interval [CI] 1.01-1.31, p = 0.0342). Compared with stable MCI, strong anticholinergics did not influence the reversion of MCI to normal cognition (OR 0.95, 95% CI 0.86-1.05, p = 0.3266). CONCLUSION: De-prescribing interventions in older adults with normal cognition should test anticholinergics as potentially modifiable risk factors for cognitive impairment.
引用
- Campbell NL, Lane KA, Gao S, et al. Anticholinergics Influence Transition from Normal Cognition to Mild Cognitive Impairment in Older Adults in Primary Care. Pharmacotherapy. 2018. PMID: 29600808. doi:10.1002/phar.2106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。